New research indicates that treating patients with esophageal cancer with proton therapy produces fewer toxic side effects than utilizing older radiation therapies.
Researchers have reported safely using immune cells grown from patients' own bone marrow to treat multiple myeloma, according to clinical trial data.
Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.
Researchers have quantified the mutational profiles for cell clusters in individual colorectal cancer tumors that have metastasized.
A new strategy targeting a protein that drives melanoma growth has been proposed in a research report.
Trials results indicate that the pioneering drug olaparib, which targets inherited mutations, can be beneficial for men with prostate cancer.
Accurate administration of proton radiotherapy in mobile organs, such as the lung, can be difficult, but researchers have developed a model that will allow for better beam targeting.
Investigators have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, a discovery that may lead to a new melanoma target or prompt new designs for treatment.
A new triple combination therapy has shown signs that it can more effectively control advanced melanoma that previous, dual-therapy combinations.
A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.
A new online tool uses a patient's molecular characteristics and provides feedback from an expert panel to help oncologists with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC).
Working with cells taken from children with a rare form of brain cancer, scientists have identified a genetic pathway that may spur cancer cell growth and resistance to anticancer treatment.
Researchers have identified a new therapeutic target for a particularly aggressive form of ovarian cancer, opening the door to effective targeted therapy development.
Researchers have developed a device that uses electric fields to drive chemotherapy drugs through the protective barrier of tissue and directly into pancreatic tumors, preventing their growth.
The therapeutic agent SapC-DOPS may have use in lung cancer treatment, according to a new study .
A recent study suggests that targeting a key enzyme and its associated metabolic programming could lead to a novel drug development for lung cancer treatment.
Targeting a specific cell survival protein could be key to treating some lymphomas, including those with genetic defects that make them resistant to standard therapies.
Women with stage 1 HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were unlikely to suffer cancer recurrence within 3 years of treatment.
Researchers believe they may have found a molecule-based approach to halting the destructive quality of the 3q26.2 amplicon, a frequent chromosomal aberrations seen in many cancers, including ovarian and breast cancers.
An oral targeted agent has shown encouraging activity and limited side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), according to research.
Patients with advanced leukemia, when treated with a new type of cancer therapy that blocks mutated IDH2 protein, showed dramatic results in a clinical trial.
A DNA vaccine targeting the breast cancer-associated antigen mammaglobin-A was proven safe and found to effectively elicit immune responses in women with metastatic breast cancer, according to a new study.
Researchers are now examining specific genetic mutations from a more Darwinian standpoint, to aid cancer treatment.
Personalized medicine is changing oncology nursing. This primer explains best practices for collecting and preparing biospecimens used to guide therapy.
Precision cancer treatment examines tumors on a genetic level with an aim to uncover the cause of the cancer's growth.
Glioblastoma multiforme (GBM) is one of the most lethal primary brain tumors, but new therapeutic strategies are being investigated.
Targeting BRAF V600E/K mutation-positive melanoma with dabrafenib in combination with trametinib achieves longer overall survival and impoved response rates, compared to treatment with vemurafenib alone.
Treatment with the drug crizotinib has been effective for stopping lung tumor growth driven by rearrangements of the ROS1 gene.
- Growing up with cancer: Understanding the challenges to adolescents and young adults (AYAs) coping with cancer
- Navigators have a key role in using genetics and genomics for cancer risk identification
- Using the navigation process to improve both your program and your patient outcomes
- Pilot program coordinates palliative care and support for rural communities
- Composing a CoC-compliant community health needs assessment (CHNA)
- Survivorship care plans: The shift back to primary care
- Scientists identify key to preventing metastatic breast cancer
- Noninvasive colon cancer screening promising for African Americans
- Cancer and intimate partner violence: Could you tell if one of your patients is a victim?
- Blood test detects breast cancer metastasis early
- Comorbid conditions associated with worse lung cancer survival
- Benefits found for screening colonoscopies of higher quality
- High-grade cervical lesions declining in young women
- Early relapse of follicular lymphoma may increase risk of death
- Study identifies perception gap in incidence, impact of CINV/RINV
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|